SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 （於香港註冊成立的有限公司） （股份代號：3681） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 茲提述中國抗體製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）所刊發 日 期 為 二 零 二 二 年 二 月 十 六 日 、 二 零 二 二 年 三 月 十 四 日 、 二 零 二 二 年 六 月 十 五 日 、 二 零 二 三 年 五 月 二 十 二 日 、 二 零 二 三 年 六 月 十 二 日 、 二 零 二 三 年 八 月 十 四 日、二零二三年九月十一日、二零二三年十一月二十七日、二零二四年六月十一 日、二零二五年四月七日、二零二五年十月十四日、二零二五年十二月十一日、 二零二六年二月二十四日及二零二六年三月二十五日的公告，內容有關本集團主 要產品之一SM17研發進展的最新資料 ...

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The report highlights the emergence of local companies in the allergic asthma drug market, which are leveraging policy changes and technological advancements to challenge multinational corporations' dominance [17][18] Market Background - The report outlines that allergic asthma is primarily driven by Th2 cell-mediated immune mechanisms and is associated with other allergic conditions [5] - The market is evolving from a focus on inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to include biologics and targeted therapies, reflecting a significant transformation in treatment approaches [6] Market Status - The Chinese allergic asthma drug market is experiencing robust growth, with over 40 million patients and nearly one million new cases annually, leading to increased drug demand [7][8] - The report notes that the global allergic asthma patient population is expected to rise from 471.3 million in 2018 to 560.6 million by 2030, with China's growth slightly outpacing the global average [11][12] Market Competition - The competitive landscape is characterized by a mix of multinational corporations and local innovators, with companies like GSK and AstraZeneca maintaining significant market shares through established product lines and clinical data [16][17] - Local companies are capitalizing on the "patent cliff" effect and are making strides in the development of biosimilars and targeted therapies, thereby reshaping the competitive dynamics [17][18] Development Trends - The report identifies several key trends, including the acceleration of precision medicine and targeted therapies, the breakthrough of domestic inhalation formulations, and the integration of digital technologies in patient management [33][34][37] - The shift towards a multi-faceted market driven by policy reforms and the coexistence of innovative and cost-effective generic drugs is highlighted as a significant trend [36]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The competitive landscape is evolving, with multinational companies like GlaxoSmithKline and AstraZeneca facing challenges from local firms that are leveraging policy changes and technological advancements to capture market share [16][17] Market Background - The report outlines the definition of allergic asthma, emphasizing its association with Th2-mediated immune responses and its links to other allergic conditions [5] - The market is experiencing a profound transformation, moving from traditional inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to targeted therapies that address specific inflammatory pathways [6] Market Status - The market is characterized by a strong demand for innovative treatments, with over 40 million patients in China and nearly one million new cases annually, leading to a significant increase in drug demand [7][8] - The supply side includes a variety of treatment options, including chemical drugs, allergen immunotherapy (AIT), and biologics, with a focus on improving patient adherence and treatment outcomes [9][10] Market Competition - The competitive assessment includes product innovation capability, market share, and strategic research and development (R&D) positioning as key dimensions for evaluating leading companies in the allergic asthma drug sector [13][14][15] - The report identifies ten recommended brands, highlighting their innovative products and market positions, such as Mabtech's CMAB007 and AstraZeneca's inhalation solutions [21][22][24] Development Trends - The report discusses several key trends shaping the future of the allergic asthma drug market, including the acceleration of precision medicine, advancements in inhalation device technology, and the impact of policy reforms on market dynamics [32][33][34][36][37] - Digitalization and the integration of healthcare services are expected to enhance patient management and treatment adherence, creating a more comprehensive ecosystem for asthma care [37]

Core Insights - The article discusses the approval of a new BCL2 inhibitor, Baiyueda (Sotuklara), by the National Medical Products Administration in China for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory mantle cell lymphoma (MCL) patients, marking a significant advancement in the treatment of blood cancers in China [1][4][6]. Industry Overview - Blood cancers, including lymphomas, multiple myeloma, and leukemia, have shown a significant increase in incidence, with lymphomas now being the most common type of blood cancer in China [2][3]. - The rise in cases is particularly notable among older populations, with chronic lymphocytic leukemia and mantle cell lymphoma seeing a marked increase in diagnoses [2]. Treatment Advancements - Traditional treatment methods for CLL and SLL have evolved, with chemotherapy being replaced by targeted therapies such as BTK inhibitors, which have shown superior efficacy [3][4]. - The introduction of BCL2 inhibitors, particularly Sotuklara, represents a breakthrough in treatment, offering new options for patients who are not suitable for chemotherapy [4][5]. Mechanism and Efficacy - BCL2 inhibitors work by specifically binding to and inhibiting the BCL2 protein, which prevents cancer cells from undergoing apoptosis, thus promoting cell death in blood cancers [6]. - Sotuklara has demonstrated strong efficacy and safety in preliminary clinical trials, providing a new treatment pathway for patients with relapsed or refractory conditions [4][5]. Future Potential - The potential of BCL2 inhibitors lies in their ability to shift treatment paradigms from continuous therapy to limited-duration treatment, allowing for deep molecular remissions and potentially long-term disease-free survival [6][7]. - The treatment goals for CLL and MCL have evolved from merely controlling the disease to achieving deep molecular remissions and exploring potential cures [7]. Market and Accessibility - The approval of innovative drugs like Sotuklara signifies China's progress in the blood cancer treatment landscape, moving from a follower to a leader in the field [8]. - Ensuring patient access to these new therapies is crucial, with calls for the inclusion of such drugs in national insurance schemes to alleviate financial burdens on patients [8][9]. Clinical Leadership - The Shandong University Qilu Hospital's hematology department is recognized as a national center for lymphoma treatment, contributing significantly to the development and application of new therapies [10][11]. - The department aims to enhance the quality of care and expand access to innovative treatments for patients in the region [11].

Investment Rating - The report does not explicitly provide an investment rating for the rare disease industry. Core Insights - The rare disease sector is characterized by significant policy evolution and market trends, with a focus on the accessibility of treatments and the development of orphan drugs [1][2][5]. Summary by Sections Overview of the Rare Disease Industry - The report analyzes the policies regarding rare diseases in China, the United States, Japan, and Europe, highlighting the differences in definitions and management frameworks across these regions [6][12]. - China has included 207 diseases in its rare disease directory, while the U.S. has no unified directory but manages information through the GARD database [10][11]. Patient Population and Management Status - The report indicates that rare diseases affect over 200 million people globally, with China having more than 20 million affected individuals [12][14]. - The management systems in China are still developing, with significant gaps in data accuracy and epidemiological tracking compared to established systems in the U.S. and Europe [13][14]. Drug Availability and Accessibility - As of 2024, China has approved 55 rare disease drugs, while the U.S. has approved 26, and the EU has approved 15 [15][16]. - The report notes that 70.5% of rare diseases globally have available treatments, but many patients in China still face challenges in accessing these medications due to high costs and limited insurance coverage [16][17]. Leading Companies in Rare Disease Drug Development - The report identifies key players in the rare disease drug development space, emphasizing the growing pipeline of domestic research in China, although it still lags behind international pharmaceutical companies in innovation [16][17].

Core Insights - The successful launch of the "Acalabrutinib 1L CLL/SLL Indication Medical Insurance Implementation Press Conference" during the CSCO meeting highlights the clinical significance of Acalabrutinib's inclusion in medical insurance for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [1][2] - Acalabrutinib has previously been included in medical insurance for three lymphoma-related indications, covering various clinical scenarios in lymphoma treatment [1] - The median age of CLL patients in China is 65, with an increasing incidence due to an aging population and improved diagnostic capabilities, posing a significant health threat to the elderly [1] Group 1 - The rise of targeted therapies has transformed the treatment model for CLL, with Acalabrutinib leading the shift towards a "chemotherapy-free era" [2] - Phase III studies show that after 12 months of treatment with Acalabrutinib, the progression-free survival (PFS) rate is 93.1%, and after 18 months, the overall survival (OS) rate is 96.7% [2] - The inclusion of Acalabrutinib in medical insurance as of January 1, 2026, represents a critical transition from "available" to "accessible" for a broader patient population [2] Group 2 - The implementation of Acalabrutinib in medical insurance significantly reduces the economic burden on patients and accelerates the transition from chemotherapy to a chemotherapy-free treatment model [2] - Ongoing exploration of Acalabrutinib combination therapies aims to achieve deeper remission and promote individualized, precise treatment approaches [2] - Evidence from registration studies indicates that Acalabrutinib monotherapy for relapsed/refractory CLL patients shows a complete response (CR) rate of 26.3% after a median follow-up of 33.1 months, with a discontinuation rate of only 7.5% and no incidence of grade 3 or higher atrial fibrillation [2]

Core Viewpoint - The article emphasizes the increasing incidence of lymphoma due to the aging population in China, while highlighting that modern medical advancements have made it a controllable disease. Awareness of health, attention to abnormal body signals, and timely medical consultation are crucial in addressing lymphoma [1]. Group 1: Types of Lymphoma - Lymphoma is primarily categorized into Hodgkin lymphoma and non-Hodgkin lymphoma, with Hodgkin lymphoma being relatively rare, accounting for about 10% of cases. Non-Hodgkin lymphoma is more common and complex, with various subtypes. The distinction between these two types is fundamental for diagnosis and influences treatment strategies and prognosis [2]. Group 2: Symptoms of Lymphoma - The most common initial symptoms of lymphoma include progressive, painless, and hard lymph node enlargement in areas such as the neck, armpit, or groin. Other clinical symptoms may include fever, night sweats, and weight loss [3]. Group 3: Diagnosis of Lymphoma - Lymph node biopsy is the gold standard for diagnosing lymphoma, where a sample of affected tissue is examined to confirm the presence of lymphoma and determine its subtype. Additional tests, including blood, imaging, and bone marrow examinations, may be conducted to assess the condition [5]. Group 4: Treatment of Lymphoma - The main treatment modalities for lymphoma include chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Chemotherapy is a systemic treatment that targets rapidly proliferating malignant cells, while radiotherapy is a localized treatment that uses high-energy rays to damage tumor DNA. Targeted therapy specifically interferes with tumor cell growth, and immunotherapy enhances the body's immune response against tumors [5]. Group 5: Recovery and Management - With advancements in medical technology, the cure rate for lymphoma has significantly improved. Most patients achieve good outcomes through standardized and comprehensive treatment. Post-treatment recovery is also vital, requiring regular check-ups, exercise, and maintaining a positive lifestyle [6]. Group 6: Expert Commentary - The article provides a detailed overview of lymphoma types, symptoms, diagnostic methods, and treatment options, while emphasizing the importance of recovery management, such as regular check-ups and healthy living. The structure is clear and content-rich, making it suitable for public reading and helping to alleviate fears and boost confidence in overcoming the disease [7].

Core Insights - The incidence of thyroid cancer is rising significantly across 185 countries, with six countries reporting an annual increase of over 10%. The prevalence among individuals aged 15-39 has been increasing over the past two decades [1] Group 1: Factors Contributing to Increased Incidence - The rise in thyroid cancer rates is attributed to multiple factors, including increased detection of small tumors (less than 1 cm) due to improved ultrasound screening methods [2] - Environmental changes, such as living near nuclear accident sites (e.g., Chernobyl, Fukushima), have been linked to higher thyroid cancer rates [2] - Lifestyle factors such as diet, iodine intake, air pollution, and increased use of electronic devices are also under scrutiny, although strong evidence linking these factors to thyroid cancer is still lacking [2] Group 2: Young Population and Thyroid Cancer - Young individuals face increased stress, irregular eating habits, and emotional fluctuations, which may disrupt the endocrine system and elevate the risk of thyroid diseases [3] - Obesity among young people has been identified as a risk factor for developing thyroid cancer [4] Group 3: Treatment Advances - Overall prognosis for thyroid cancer is favorable, with the most common type, papillary thyroid cancer, having a 5-year survival rate of around 90% [5] - Personalized treatment approaches are now favored over traditional "one-size-fits-all" methods, particularly for low-risk patients who may not require immediate surgery [6] - New surgical techniques, such as transaxillary and transoral approaches, minimize visible scarring, while minimally invasive ablation techniques are emerging as important treatment options for suitable cases [7] - Targeted therapies have provided new hope for patients with advanced thyroid cancer, allowing for more effective treatment based on genetic mutations associated with the disease [7] Group 4: Public Perception and Awareness - While the trend of younger individuals being diagnosed with thyroid cancer is concerning, experts emphasize that advancements in screening and treatment have significantly improved the cure rates for early-stage thyroid cancer [8]

Core Insights - The "People's Good Doctor Jinshan Camellia Plan" conference highlighted advancements in cancer prevention and control, focusing on high-quality development in the field [1] Group 1: Cancer Treatment Advances - Hepatobiliary tumor treatment has entered an immune-dominant phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [1] - Lung cancer patients have seen improved survival rates due to the promotion of precision diagnosis and treatment, with breakthroughs in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [2] - Innovative drugs and treatment strategies in esophageal and gastric cancers have led to significant clinical advancements, although challenges in standardization and precision screening remain [2] Group 2: Multidisciplinary Collaboration - A multidisciplinary collaboration model is becoming mainstream in cancer treatment, allowing for personalized treatment plans through joint consultations among various specialists [4] - There is a need for improved management of patient follow-ups and a more balanced regional development in cancer prevention and treatment [4] Group 3: Emerging Treatment Modalities - Immunotherapy combined with chemotherapy has become a first-line treatment for advanced nasopharyngeal carcinoma, with ongoing exploration of different intervention models [3] - The application of CAR-T cell therapy and targeted drugs has provided long-term survival opportunities for previously hard-to-treat hematological cancer patients [3] Group 4: Future Directions - Continuous innovation in clinical research and acceleration of new treatment technologies are essential for enhancing cancer prevention and treatment systems [5] - The focus should be on early screening, diagnosis, and treatment management to provide patients with better survival prospects [5]

Core Viewpoint - Recent cases of thyroid cancer among public figures have brought renewed attention to thyroid health issues, highlighting the increasing incidence of thyroid cancer globally and in China [1][2]. Group 1: Incidence and Characteristics of Thyroid Cancer - Thyroid cancer is the most common tumor in the endocrine system, with a significant rise in incidence. In China, the incidence rate increased 20 times from 2000 to 2016, with 466,000 new cases reported in 2022 [1][3]. - The overall development of thyroid cancer is slow, particularly for papillary thyroid cancer, which constitutes about 80% of cases. Many patients experience minimal changes over 5-10 years, and lymph node metastasis rates are low [1][2]. - The incidence rate of thyroid cancer among women in China is particularly high, with a rate of 49.4 per 100,000, making it one of the most common cancers among women [3]. Group 2: Treatment Approaches - Surgical intervention remains the primary treatment for thyroid cancer, with a trend towards preserving thyroid function rather than total thyroidectomy for low-risk patients. High-risk patients may require total thyroidectomy [2][4]. - There is ongoing debate regarding the appropriateness of ablation therapy for certain patients, and the decision-making process for surgery is complex, especially for small tumors [5][4]. Group 3: Emerging Therapies and Drug Approvals - Recent advancements in targeted therapies and immunotherapy for high-risk thyroid cancer have shown some promise, although overall efficacy remains suboptimal [6]. - Several new drugs for thyroid cancer have been approved in China since 2022, including broad-spectrum anti-cancer drugs and specific treatments for differentiated thyroid cancer [7][8]. Group 4: Public Perception and Awareness - The term "lazy cancer" is misleading, as it may downplay the seriousness of certain aggressive forms of thyroid cancer. High-risk cases account for 10-20% of all thyroid cancer cases, translating to thousands of new cases annually in China [9].